Report : Asia Pacific Needle-Free Injection Systems Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Fillable Needle-free Injectors and Prefilled Needle-free Injectors), Technology (Jet-Based Needle-free Injectors, Spring-Based Needle-free Injectors, Microarray Patch Injectors, and Others), Type (Liquid-Based Needle-free Injectors, Projectile-based Needle-free Injectors, and Powder-Based Needle-free Injectors), Usability (Disposable and Reusable), Site of Delivery (Subcutaneous Injectors, Intramuscular Injectors, and Intradermal Injectors), Application (Vaccine Delivery, Insulin Delivery, Oncology, Pain Management, Dermatology, and Others), and End User (Hospitals, Home Care Settings, Research Laboratories, Pharmaceutical & Biotechnological Companies, and Other End User)
At 18.2% CAGR, the Asia Pacific Needle-Free Injection Systems Market is speculated to be worth US$ 89.30 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific needle-free injection systems market was valued at US$ 32.68 million in 2022 and is expected to reach US$ 89.30 million by 2028, registering a CAGR of 18.2% from 2022 to 2028. Advantages of using self-injection devices and rising demand for vaccines and biosimilars are the critical factors attributed to the Asia Pacific needle-free injection systems market expansion.
Parenteral is often considered the default drug delivery route but is also an implausible process. Increasing the use of innovative technologies such as use of artificial intelligence (AI), bar code identification (BI), telecare, e-prescription, and others can help clinicians and pharmacists in many ways by allowing the storage of patient planned proceedings, patient records and smoothening the vaccination process. As a result, many pharmaceutical manufacturers have embraced IT technology owing to various benefits of automated IT and provide painless and effective drug delivery systems that can benefit the patients. For instance, Nemera developed a customizable platform—Safe’n’Sound. It is an add-on passive safety device for a prefilled syringe that is aimed at preventing potential needlestick injuries by stimulating a feature that automatically activates at the end of the injection and simplifies the injection process. Healthcare workers had to deal with various challenges due to NSIs, but the burden of these injuries has reduced with the changing technology. A few of the key players in the Asia Pacific needle-free injection systems market such as Portal Instruments, PharmaJet, among others, are focusing on developing innovative products such as micro-array patches, digital needle free injectors, and wearable needle free insulin injectors to deal with issues related to outmoded challenges related to breakage, leakage, and needlestick prevention. Thus, with the surge in new technologies, the demand for needle free injection systems is expected to grow during the forecast period.
On the contrary, higher development costs of needle free injectors compared to conventional injection systems hurdles the growth of Asia Pacific needle-free injection systems market.
Based on product, the Asia Pacific needle-free injection systems market is sub segmented into fillable needle-free injectors and prefilled needle-free injectors. The fillable needle-free injectors segment held 63.1% share of the Asia Pacific needle-free injection systems market in 2022, amassing US$ 20.63 million. It is projected to garner US$ 55.53 million by 2028 to expand at 17.9% CAGR during 2022–2028.
Based on technology, the Asia Pacific needle-free injection systems market is segmented into jet-based needle-free injectors, spring-based needle-free injectors, microarray patch injectors, and others. The jet-based needle-free injectors segment former held 33.6% market share in 2022, amassing US$ 10.98 million. It is projected to garner US$ 39.78 million by 2028 to expand at 18.0% CAGR during 2022–2028.
Based on type, the Asia Pacific needle-free injection systems market is segmented into liquid-based needle-free injectors, projectile-based needle-free injectors, and powder-based needle-free injectors. The liquid-based needle-free injectors segment held 70.4% market share in 2022, amassing US$ 23.02 million. It is projected to garner US$ 62.25 million by 2028 to expand at 18.0% CAGR during 2022–2028.
Based on durability, the Asia Pacific needle-free injection systems market is bifurcated into disposable and reusable. With 59.3% share of the domain, the reusable segment dominated the market in 2022. It accrued US$ 19.36 million in 2022 and is estimated to generate US$ 52.06 million by 2028 to grow at a CAGR of 17.9% over the forecast period.
Based on site of delivery, the Asia Pacific needle-free injection systems market is segmented into subcutaneous injectors, intramuscular injectors, and intradermal injectors. The subcutaneous injectors segment held 50.2% market share in 2022, amassing US$ 16.39 million. It is projected to garner US$ 45.81 million by 2028 to expand at 18.7% CAGR during 2022–2028.
Based on application, the Asia Pacific needle-free injection systems market is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology, and others. The vaccine delivery segment held 33.0% market share in 2022, amassing US$ 10.80 million. It is projected to garner US$ 30.60 million by 2028 to expand at 19.0% CAGR during 2022–2028.
Based on end user, the Asia Pacific needle-free injection systems market is segmented into hospitals, home care settings, research laboratories, pharmaceutical and biotechnology companies, and others. The hospitals segment held 33.8% market share in 2022, amassing US$ 11.03 million. It is projected to garner US$ 30.90 million by 2028 to expand at 17.9% CAGR during 2022–2028.
Based on country, the Asia Pacific needle-free injection systems market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 25.7% market share in 2022. It was assessed at US$ 8.41 million in 2022 and is likely to hit US$ 23.79 million by 2028, exhibiting a CAGR of 18.9% during the forecast period.
Key players dominating the Asia Pacific needle-free injection systems market are Aijex Pharma International Inc.; Crossject; Ferring B.V.; Medical International Technologies (MIT Canada) Inc.; NuGen Medical Devices; and Zealand Pharma A/S, among others.
- In June 2022, NuGen Medical Devices Inc., a leader in needle-free drug delivery, has announced that it will be launching a needle-free injection device specifically designed for domesticated household pets. The PetJet will allow pet owners and veterinarians to safely and quickly inject various types of medication without the fear of hurting their pets with a traditional hypodermic needle.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com